Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Butterfield out, Sedgwick in as Alliance Pharma CEO
(Sharecast News) - Alliance Pharma announced a significant leadership transition on Wednesday, with chief executive Peter Butterfield stepping down from his role to pursue other business interests. The AIM-traded firm said Butterfield joined its board in 2010 and assumed the CEO position in 2018.
To fill the vacancy, Alliance said it had conducted a search process and appointed Nick Sedgwick as the new CEO, effective from 13 May.
It said Sedgwick would bring a wealth of experience in consumer health, with a career spanning 30 years across European, US, and global roles at major multinational companies including Reckitt, Coty, and Nestlé.
His most recent role was as regional director for UK and Ireland consumer health at Reckitt, where he increased revenue and profitability in one of the company's key markets.
Prior to his tenure there, Sedgwick held various senior positions at Coty, including senior vice-president for global sales and commercial capabilities, and general manager of consumer beauty for the UK and Ireland.
Butterfield would continue to support Alliance until 30 June, facilitating the transition to Nick Sedgwick's leadership.
"The board and I would like to thank Peter for everything that he has done for Alliance," said chair Camillo Pane.
"He led Alliance's transition towards consumer healthcare and group revenues have almost doubled since he became CEO.
"We welcome Nick to Alliance and look forward to working with him as he leads the company through the next phase of its growth and development."
At 1231 BST, shares in Alliance Pharma were down 15.17% at 27.15p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
